Mapping the Landscape of Pain: A Registry's First Year Offers New Hope

SUWANEE, Ga. – June 10, 2026 – For the 740 people who have meticulously detailed their experiences with one of the most excruciating conditions known to medicine, the past year has been about more than just data entry. It has been an act of hope. This week, the Facial Pain Association (FPA) celebrated the first anniversary of its Facial Pain Registry, a groundbreaking initiative that is transforming individual stories of suffering into a powerful, collective resource for scientific discovery.

Developed in partnership with the National Organization for Rare Disorders (NORD®) and built on its sophisticated IAMRARE® platform, the registry has, in just twelve months, established a formidable body of patient-reported data. This isn't just a milestone for the FPA; it's a potential turning point for the millions worldwide who navigate the isolating and often-invisible world of neuropathic facial pain.

A New Foundation for an Unseen Illness

To understand the significance of the registry, one must first understand the brutal nature of the conditions it seeks to illuminate. Neuropathic facial pain disorders, such as trigeminal neuralgia (TN), are not simple headaches. TN, often called the "suicide disease," is characterized by sudden, severe, electric shock-like or stabbing pains in the face. These attacks can be triggered by the most benign stimuli: a cool breeze, a touch, chewing, or even speaking. Affecting an estimated four to five out of every 100,000 people, its rarity is a double-edged sword, contributing to a profound lack of understanding in the medical community.

Patients frequently spend years on a diagnostic odyssey, bounced between doctors and dentists, misdiagnosed, and prescribed ineffective treatments. The registry was created to cut through this confusion. "The first year of the Facial Pain Registry represents something we have never had before - a structured, growing body of data that reflects the true experience of people living with neuropathic facial pain," said Melissa Baumbick, Chief Executive Officer of the Facial Pain Association. "Every participant who completed a survey has contributed something that no clinical study alone can capture: their story."

This collection of stories provides a panoramic view of the patient journey, capturing data on everything from the characteristics of the pain to medical history. By aggregating these experiences, the registry offers researchers a chance to identify patterns that are invisible at the individual clinical level, potentially uncovering new insights into comorbidities, risk factors, and the true quality-of-life impact of these disorders.

The Architecture of Hope: Data, Security, and Partnership

The registry's success hinges on a powerful combination of patient advocacy and technological expertise. The partnership between the FPA, a leading voice for the facial pain community, and NORD, a veteran in the rare disease space, provides a model for patient-centered research. The IAMRARE® platform is a testament to this, a cloud-based system designed to be secure, mobile-friendly, and, above all, respectful of the individuals contributing their most sensitive health information.

Trust is the currency of any patient registry. NORD's 40-year history of community engagement is baked into the platform's DNA. Data is confidential and de-identified, meaning it cannot be traced back to an individual by researchers who access it. However, a securely encrypted link is maintained, allowing the FPA to re-contact a participant—with their prior consent—if they might be a candidate for a specific clinical trial or study. This gives patients control, allowing them to decide the extent of their involvement while ensuring their privacy is paramount. This structure empowers patient advocacy groups like the FPA to own and control their data, ensuring it is used in service of the community it represents.

From Patient Stories to Scientific Insight

The registry has already become a beacon for the research community. In its first year, it has attracted significant inquiries from academic institutions and pharmaceutical companies alike. The questions being asked reveal the breadth of the registry's potential. Researchers are eager to explore the data to better understand the link between trigeminal neuralgia and temporomandibular disorders (TMD), to build sociodemographic profiles of patients, and to assess the potential of novel treatments like non-invasive brain stimulation.

This interest confirms that the registry is filling a critical void. By providing a real-world, longitudinal dataset, it allows scientists to study the natural history of the disease—how it evolves over time—and evaluate the effectiveness of existing treatments in a way that is not possible in a traditional, short-term clinical trial. To deepen this resource, the FPA is already developing two new surveys set to launch later this year. One will focus on the complex landscape of medications—what works, what doesn't, and the side effects—while the other will tackle the profound mental and emotional toll of living with chronic, severe pain.

Charting the Path Forward

The collection of data is only the first step. The true measure of the registry's impact will be the research it enables. The FPA is now finalizing its formal process for evaluating research proposals and expects to begin accepting submissions by the fall of 2026. This will mark the registry's transition from a data repository to an active engine of discovery.

A dedicated Registry Advisory Board, comprising researchers, clinicians, FPA staff, and patient advocates, will oversee the process, ensuring that the research is ethical, scientifically sound, and aligned with the community's most pressing needs.

The initiative is also looking outward. While the majority of the initial 740 participants are from the United States, a significant 13% are international. Recognizing that pain knows no borders, the FPA has plans to translate the registry into additional languages, expanding its global reach and ensuring the data reflects the full, diverse spectrum of the facial pain experience. For participants, the journey continues with an invitation to update their information annually, a crucial step that allows researchers to track changes over time. It is this long-term commitment, from both the organization and the patients themselves, that holds the power to finally change lives, turning years of isolated pain into a shared map toward a better future.